MedTrace Logo

Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

NCT02125071 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-10-18

No results posted yet for this study

Summary

An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.

Conditions

Interventions

OTHER

Blood Sample Collection

Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.

Sponsors & Collaborators

  • Green Cross Corporation

    collaborator INDUSTRY

  • Dong-Gu Kim

    lead OTHER

Principal Investigators

  • Dong Gu Kim, MD, PhD · The Catholic University, Seoul St Mary Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02125071 on ClinicalTrials.gov